Table 2.
Prognostic factors related to Hodgkin and Reed-Sternberg cells
| Factor | Function | Number of patients | Expression level (%) | Significance, univariatea | Significance, multivariatea | Reference(s) |
|---|---|---|---|---|---|---|
| HLA class II | Immune response | 292 | 59 | + (↓FFS, OS) | + (↓FFS) | [51] |
| Topoisomerase II | DNA synthesis | 238 | 64 | + (↓FFS) | + (↓FFS) | [52] |
| 146 | 49 | + (↓EFS) | +(↓EFS) | [49] | ||
| MAL | T-cell activation | 86 | 19 | + (↓FFS, OS) | +(↓FFS, OS) | [54] |
| 81 | NA | + (↓FFS, OS) | + (↓FFS) | [50] | ||
| CD20 | B-cell activation (?) | 598 | 22 | - | - | [74] |
| 248 | 11 | + (↓TTF, OS) | + (↓TTF, OS) | [73] | ||
| 119 | 20 | + (↑TTF) | + (↑TTF) | [75] | ||
| 166 | 12 | - | - | [68] | ||
| 59 | 25 | + (↑PFS) | + (↑PFS) | [48] | ||
| p53 | Apoptosis; response to genotoxic stress | 194 | 57 | + (↓DFS, OS) | + (↓DFS, OS) | [44] |
| 49 | 40 to 75b | - | - | [42] | ||
| 78 | 67 | - | - | [43] | ||
| 259 | 29 | + (↓EFS, DSS) | + (↓EFS, DSS) | [45] | ||
| 140 | 92 | - | - | [46] | ||
| 107 | 10 | - | - | [47] | ||
| Bcl-2 | Cell survival; anti-apoptosis | 140 | 61 | - | - | [46] |
| 107 | 26 | + (↓FFS, OS) | +(↓FFS, OS) | [47] | ||
| 707 | 61 | + (↓FFS) | +(↓FFS) | [33] | ||
| 194 | 47 | + (↓DFS) | + (↓DFS) | [44] | ||
| 81 | NA | - | + (↓FFS) | [50] | ||
| 146 | 40 | - | - | [49] | ||
| 59 | 33 | + (↓PFS) | + (↓PFS) | [48] |
aThe presence (+) or absence (-) of a significant correlation (positive ↑ or negative ↓) with the study endpoints.
bTwo different antibodies against p53 were used in this study.
Bcl-2, B-cell lymphoma 2; DSS, disease-specific survival; EFS, event-free survival; FFS, failure-free survival; HLA, human leukocyte antigen; MAL, myelin and lymphocyte protein; NA, not applicable; OS, overall survival; PFS, progression-free survival; TTF, time to treatment failure.